A New Hope for Atrial Fibrillation Patients with Breakthrough Catheter Technology
BTL, a leader in medical innovation, is proud to announce a major…
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
Phase 3 trial results published in European Journal of Heart Failure identify…
Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson’s Disease Patients
HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE…
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)
Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients…
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)
Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients…
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)
Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients…
Attruby (acoramidis), a Near Complete TTR Stabilizer (90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
- Attruby is the first and only approved product with a label…
Attruby (acoramidis), a Near Complete TTR Stabilizer (90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
- Attruby is the first and only approved product with a label…
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on…
2024 Access to Medicine Index finds that pharma companies are missing opportunities to reach more patients in low- and middle-income countries
AMSTERDAM, Nov. 19, 2024 /PRNewswire/ -- The 2024 Access to Medicine Index…